Ongoing Vaccine and Monoclonal Antibody HIV Prevention Efficacy Trials and Considerations for Sequel Efficacy Trial Designs

Peter B. Gilbert

arxiv: 1906.08409 · v1 · pith:7XMX3VQVnew · submitted 2019-06-20 · 📊 stat.AP

Ongoing Vaccine and Monoclonal Antibody HIV Prevention Efficacy Trials and Considerations for Sequel Efficacy Trial Designs

Peter B. Gilbert This is my paper

Pith reviewed 2026-05-25 19:31 UTC · model grok-4.3

classification 📊 stat.AP

keywords HIV preventionvaccine efficacy trialsmonoclonal antibody trialscorrelates of protectionclinical trial designsequel trialsHIV-1 incidencesurrogate endpoints

0 comments

The pith

Correlates of protection analyses from ongoing HIV prevention trials will shape the design of sequel efficacy studies.

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The paper summarizes four ongoing randomized placebo-controlled trials testing vaccines or monoclonal antibodies to prevent HIV-1 infection in different populations. It lays out three main statistical challenges for planning the next round of trials: incorporating new prevention tools into study arms or standards of care, choosing trial features based on what the current trials find about overall efficacy and about immune markers, and handling the possibility that HIV incidence will be too low for conventional designs to work well. The author focuses on how secondary analyses that link host immune markers and viral features to infection risk and to how well prevention works will guide those choices, with special weight for the antibody trials where serum neutralization potency and coverage are hypothesized in advance to stand in for actual infection prevention.

Core claim

The results of correlates of protection analyses, which ascertain how different host immunological markers and HIV-1 viral features impact HIV-1 risk and prevention efficacy, have an important influence on sequel trial design. This influence is especially relevant for the monoclonal antibody trials because of the focused pre-trial hypothesis that potency and coverage of serum neutralization constitutes a surrogate endpoint for HIV-1 infection.

What carries the argument

correlates of protection analyses that link immunological markers and viral features to HIV-1 risk and to prevention efficacy, used to decide primary objectives and design features for follow-on trials.

If this is right

Sequel trial designs can be tailored to whether overall efficacy is demonstrated and which specific immune markers or viral features correlate with protection.
For the monoclonal antibody trials, confirmation that serum neutralization potency and coverage predict infection risk would allow future studies to use that measurement as a primary or surrogate endpoint.
Trial protocols must explicitly model the background level of other effective prevention methods so that any new intervention's added benefit can still be measured.
If incidence falls below the level needed for standard superiority testing, alternative primary objectives such as noninferiority or prevention of acquisition in high-risk subgroups become necessary.

Where Pith is reading between the lines

These are editorial extensions of the paper, not claims the author makes directly.

The same logic could extend to planning trials for other pathogens where immune markers are measured before efficacy is known.
If the correlates prove reliable, regulators might accept smaller or shorter trials that rely on the marker rather than waiting for enough infection events.
Low-incidence settings may push the field toward cluster-randomized or stepped-wedge designs that can still detect incremental gains even when background prevention is strong.

Load-bearing premise

The primary efficacy results and secondary correlates results from the four ongoing trials will arrive in time and will be clear enough to guide concrete choices about the next trials' objectives and features.

What would settle it

A situation in which the correlates analyses from the ongoing trials turn out to have little or no effect on the actual primary objectives or key design parameters chosen for the sequel trials.

Figures

Figures reproduced from arXiv: 1906.08409 by Peter B. Gilbert.

**Figure 2.** Figure 2: Antibody Mediated Prevention study schema and bnAb re [PITH_FULL_IMAGE:figures/full_fig_p005_2.png] view at source ↗

read the original abstract

Four randomized placebo-controlled efficacy trials of a candidate vaccine or passively infused monoclonal antibody for prevention of HIV-1 infection are underway (HVTN 702 in South African men and women; HVTN 705 in sub-Saharan African women; HVTN 703/HPTN 081 in sub-Saharan African women; HVTN 704/HPTN 085 in U.S., Peruvian, Brazilian, and Swiss men or transgender persons who have sex with men). Several challenges are posed to the optimal design of the sequel efficacy trials, including: (1) how to account for the evolving mosaic of effective prevention interventions that may be part of the trial design or standard of prevention; (2) how to define viable and optimal sequel trial designs depending on the primary efficacy results and secondary 'correlates of protection' results of each of the ongoing trials; and (3) how to define the primary objective of sequel efficacy trials if HIV-1 incidence is expected to be very low in all study arms such that a standard trial design has a steep opportunity cost. After summarizing the ongoing trials, I discuss statistical science considerations for sequel efficacy trial designs, both generally and specifically to each trial listed above. One conclusion is that the results of 'correlates of protection' analyses, which ascertain how different host immunological markers and HIV-1 viral features impact HIV-1 risk and prevention efficacy, have an important influence on sequel trial design. This influence is especially relevant for the monoclonal antibody trials because of the focused pre-trial hypothesis that potency and coverage of serum neutralization constitutes a surrogate endpoint for HIV-1 infection... (see manuscript for the full abstract)

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, simulated authors' rebuttal, and a circularity audit. Tearing a paper down is the easy half of reading it; the pith above is the substance, this is the friction.

Desk Editor's Note private letter to a colleague

A clear but high-level discussion of design challenges for four ongoing HIV prevention trials that flags real issues without new methods or quantitative guidance.

read the letter

This paper summarizes four ongoing randomized trials (HVTN 702, 705, 703/081, 704/085) testing vaccines or monoclonal antibodies for HIV-1 prevention and then walks through three main challenges for sequel trials: accounting for background prevention tools, using correlates of protection results to shape the next designs, and handling very low incidence rates. The strongest part is the focused section on how correlates analyses, especially the pre-specified neutralization surrogate hypothesis in the mAb trials, could shift primary objectives or endpoints in follow-on studies. That connection is stated plainly and tied directly to the listed trials. The paper does a service by pulling the trial details into one place and naming the practical constraints that statisticians will face. No new data, derivations, or simulations appear, so the contribution stays at the level of structured commentary. The soft spot is that the argument leans heavily on the premise that the ongoing trials will deliver timely and actionable correlates results, yet the text supplies no thresholds, decision rules, or sensitivity checks to show when those results would actually change a design. It flags the issue as challenge (2) and (3) but leaves the mechanics open. Minor additional limitation is the absence of any worked example showing how low incidence would alter sample size or power calculations under realistic assumptions. The piece is aimed at HIV prevention trial statisticians and protocol teams who already know the four studies; outsiders will find the trial summaries useful but the design discussion too general. It deserves peer review because the topic is timely for the subfield and the writing is direct, even though any published version would need more concrete illustrations of the design adjustments discussed.

Referee Report

1 major / 0 minor

Summary. The manuscript summarizes four ongoing randomized placebo-controlled efficacy trials of candidate vaccines or monoclonal antibodies for HIV-1 prevention (HVTN 702, HVTN 705, HVTN 703/HPTN 081, HVTN 704/HPTN 085). It discusses statistical science considerations for sequel efficacy trial designs, identifying three challenges: accounting for evolving prevention interventions, defining designs based on primary efficacy and secondary correlates-of-protection results from the ongoing trials, and handling very low expected HIV-1 incidence. The central conclusion is that correlates of protection analyses will have an important influence on sequel designs, especially for the monoclonal antibody trials via the pre-trial hypothesis that serum neutralization potency and coverage is a surrogate for infection risk.

Significance. If the outlined considerations are adopted, the discussion could help optimize resource allocation and statistical power in future HIV prevention trials amid changing standard-of-care landscapes and declining incidence. The emphasis on surrogate endpoints for mAb trials is a forward-looking contribution that aligns with statistical efficiency goals in the field.

major comments (1)

[Abstract] Abstract, paragraph on challenges (2) and (3): The assertion that correlates of protection results 'have an important influence on sequel trial design' (and especially the neutralization surrogate hypothesis for mAb trials) is load-bearing for the manuscript's main conclusion, yet the text supplies no quantitative thresholds, simulation framework, decision rules, or worked examples showing how a specific correlate finding (e.g., a given IC80 potency level or coverage metric) would change primary objectives, endpoints, or sample-size calculations.

Simulated Author's Rebuttal

1 responses · 0 unresolved

We thank the referee for the detailed review and constructive feedback. Below we respond to the single major comment.

read point-by-point responses

Referee: [Abstract] Abstract, paragraph on challenges (2) and (3): The assertion that correlates of protection results 'have an important influence on sequel trial design' (and especially the neutralization surrogate hypothesis for mAb trials) is load-bearing for the manuscript's main conclusion, yet the text supplies no quantitative thresholds, simulation framework, decision rules, or worked examples showing how a specific correlate finding (e.g., a given IC80 potency level or coverage metric) would change primary objectives, endpoints, or sample-size calculations.

Authors: The manuscript is a review and discussion paper whose purpose is to summarize the four ongoing trials and to outline the principal statistical challenges that sequel designs must address once the primary efficacy and secondary correlates results become available. The statement that correlates analyses will exert an important influence follows directly from the dependence of future objectives, endpoints, and sample-size calculations on those results; this dependence is described qualitatively in the sections addressing each trial class. The paper does not claim to deliver a quantitative design framework, simulation study, or set of decision rules, which would require the actual (still unknown) trial outcomes plus additional modeling assumptions. We therefore view the current level of detail as appropriate to the manuscript's scope. That said, we agree that a brief set of hypothetical scenarios illustrating how a strong versus null neutralization surrogate finding would alter mAb trial objectives could usefully clarify the discussion, and we are prepared to add such material in revision. revision: partial

Circularity Check

0 steps flagged

No circularity; forward-looking discussion without derivations or fitted inputs

full rationale

The paper is a discussion manuscript summarizing four external ongoing trials (HVTN 702, 705, 703/081, 704/085) and outlining statistical considerations for sequel designs. It contains no equations, parameters, or derivations. The claim that correlates-of-protection results will influence sequel designs is presented as a forward-looking expectation dependent on independent external trial outcomes, not as a result derived from any internal fit or self-referential definition. No self-citation load-bearing steps, uniqueness theorems, or ansatzes appear. The text is self-contained as expert commentary on external data streams.

Axiom & Free-Parameter Ledger

0 free parameters · 0 axioms · 0 invented entities

Abstract-only review; no mathematical model, parameters, or new entities are introduced in the provided text.

pith-pipeline@v0.9.0 · 5829 in / 1134 out tokens · 24951 ms · 2026-05-25T19:31:28.617369+00:00 · methodology

discussion (0)

Lean theorems connected to this paper

Citations machine-checked in the Pith Canon. Every link opens the source theorem in the public Lean library.

IndisputableMonolith/Foundation/RealityFromDistinction.lean reality_from_one_distinction unclear

?

unclear
Relation between the paper passage and the cited Recognition theorem.

Four randomized placebo-controlled efficacy trials... challenges... (2) how to define viable and optimal sequel trial designs depending on the primary efficacy results and secondary 'correlates of protection' results
IndisputableMonolith/Cost/FunctionalEquation.lean washburn_uniqueness_aczel unclear

?

unclear
Relation between the paper passage and the cited Recognition theorem.

surrogate endpoint evaluation methods... Prentice definition... meta-analysis methods for assessing trial-level validity

What do these tags mean?

matches: The paper's claim is directly supported by a theorem in the formal canon.
supports: The theorem supports part of the paper's argument, but the paper may add assumptions or extra steps.
extends: The paper goes beyond the formal theorem; the theorem is a base layer rather than the whole result.
uses: The paper appears to rely on the theorem as machinery.
contradicts: The paper's claim conflicts with a theorem or certificate in the canon.
unclear: Pith found a possible connection, but the passage is too broad, indirect, or ambiguous to say the theorem truly supports the claim.

Reference graph

Works this paper leans on

8 extracted references · 8 canonical work pages

[1]

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

https://www.avert.org/professionals/hiv‐around‐world/sub‐saharan‐africa/south‐africa. Baeten, J. M., D. Donnell, P. Ndase, N. R. Mugo, J. D. Campbell, J. Wangisi, J. W. Tappero, E. A. Bukusi, C. R. Cohen, E. Katabira, A. Ronald, E. Tumwesigye, E. Were, K. H. Fife, J. Kiarie, C. Farquhar, G. John‐Stewart, A. Kakia, J. Odoyo, A. Mucunguzi, E. Nakku‐Joloba, ...

work page doi:10.1056/nejmoa1108524 2012
[2]

Pre‐exposure prophylaxis to prevent the acquisition of HIV‐1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open‐label randomised trial

doi: 10.1016/S2352‐3018(16)30038‐8. McCormack, S., D. T. Dunn, M. Desai, D. I. Dolling, M. Gafos, R. Gilson, A. K. Sullivan, A. Clarke, I. Reeves, G. Schembri, N. Mackie, C. Bowman, C. J. Lacey, V. Apea, M. Brady, J. Fox, S. Taylor, S. Antonucci, S. H. Khoo, J. Rooney, A. Nardone, M. Fisher, A. McOwan, A. N. Phillips, A. M. Johnson, B. Gazzard, and O. N. ...

work page doi:10.1016/s2352 2016
[4]

Surrogate endpoints in clinical trials: definition and operational criteria

doi: 10.1128/CVI.00131‐10. Plotkin, S. A., W.A. Orenstein, P.A. Offit, and K.M. Edwards. 2018. Plotkin's Vaccines 7th ed. Philadelphia, PA: Elsevier. Prentice, R. L. 1989. "Surrogate endpoints in clinical trials: definition and operational criteria." Stat Med 8 (4):431‐40. 27 Price, B. L., P. B. Gilbert, and M. J. van der Laan. 2018. "Estimation of the op...

work page doi:10.1128/cvi.00131 2018
[5]

Placebo use in vaccine trials: recommendations of a WHO expert panel

doi: 10.1056/NEJMoa0908492. Rid, A., A. Saxena, A. H. Baqui, A. Bhan, J. Bines, M. C. Bouesseau, A. Caplan, J. Colgrove, A. Dhai, R. Gomez‐Diaz, S. K. Green, G. Kang, R. Lagos, P. Loh, A. J. London, K. Mulholland, P. Neels, P. Pitisuttithum, S. C. Sarr, M. Selgelid, M. Sheehan, and P. G. Smith. 2014. "Placebo use in vaccine trials: recommendations of a WH...

work page doi:10.1056/nejmoa0908492 2014
[6]

Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies

"Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies." Ann Intern Med 163 (2):127‐34. doi: 10.7326/M14‐1741. US Food and Drug Administration. 1998. Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. Technical report. US Food and Drug Administration. 2012. "Food and Dru...

work page doi:10.7326/m14 1998
[7]

pre‐exposure prophylaxis, PrEP) (Grant et al

and HIV‐uninfected persons (e.g. pre‐exposure prophylaxis, PrEP) (Grant et al. 2010, Molina et al. 2015, Baeten et al. 2012, McCormack et al. 2016). Behavioral interventions such as individual‐level risk reduction counseling have not demonstrated efficacy in randomized controlled trials in preventing sexual transmission of HIV [summarized in (Padian et al...

work page 2010
[8]

Compile, Analyze and Tally NAb Panels

for further discussion of this point]. For instance, medical male circumcision is durably efficacious after a single invasive procedure, whereas daily pill‐taking (e.g. oral PrEP) is non‐invasive and requires daily or near‐daily adherence (Donnell et al. 2014, Murnane et al. 2015). HIV prevention remains an area of intense research, and additional types o...

work page doi:10.1126/science.1193748 2014
[9]

Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention

doi: 10.1056/NEJMoa1506273. Murnane, P. M., E. R. Brown, D. Donnell, R. Y. Coley, N. Mugo, A. Mujugira, C. Celum, J. M. Baeten, and E. P. Study Team Partners Pr. 2015. "Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention." Am J Epidemiol 182 (10):848‐...

work page doi:10.1056/nejmoa1506273 2015

[1] [1]

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

https://www.avert.org/professionals/hiv‐around‐world/sub‐saharan‐africa/south‐africa. Baeten, J. M., D. Donnell, P. Ndase, N. R. Mugo, J. D. Campbell, J. Wangisi, J. W. Tappero, E. A. Bukusi, C. R. Cohen, E. Katabira, A. Ronald, E. Tumwesigye, E. Were, K. H. Fife, J. Kiarie, C. Farquhar, G. John‐Stewart, A. Kakia, J. Odoyo, A. Mucunguzi, E. Nakku‐Joloba, ...

work page doi:10.1056/nejmoa1108524 2012

[2] [2]

Pre‐exposure prophylaxis to prevent the acquisition of HIV‐1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open‐label randomised trial

doi: 10.1016/S2352‐3018(16)30038‐8. McCormack, S., D. T. Dunn, M. Desai, D. I. Dolling, M. Gafos, R. Gilson, A. K. Sullivan, A. Clarke, I. Reeves, G. Schembri, N. Mackie, C. Bowman, C. J. Lacey, V. Apea, M. Brady, J. Fox, S. Taylor, S. Antonucci, S. H. Khoo, J. Rooney, A. Nardone, M. Fisher, A. McOwan, A. N. Phillips, A. M. Johnson, B. Gazzard, and O. N. ...

work page doi:10.1016/s2352 2016

[3] [4]

Surrogate endpoints in clinical trials: definition and operational criteria

doi: 10.1128/CVI.00131‐10. Plotkin, S. A., W.A. Orenstein, P.A. Offit, and K.M. Edwards. 2018. Plotkin's Vaccines 7th ed. Philadelphia, PA: Elsevier. Prentice, R. L. 1989. "Surrogate endpoints in clinical trials: definition and operational criteria." Stat Med 8 (4):431‐40. 27 Price, B. L., P. B. Gilbert, and M. J. van der Laan. 2018. "Estimation of the op...

work page doi:10.1128/cvi.00131 2018

[4] [5]

Placebo use in vaccine trials: recommendations of a WHO expert panel

doi: 10.1056/NEJMoa0908492. Rid, A., A. Saxena, A. H. Baqui, A. Bhan, J. Bines, M. C. Bouesseau, A. Caplan, J. Colgrove, A. Dhai, R. Gomez‐Diaz, S. K. Green, G. Kang, R. Lagos, P. Loh, A. J. London, K. Mulholland, P. Neels, P. Pitisuttithum, S. C. Sarr, M. Selgelid, M. Sheehan, and P. G. Smith. 2014. "Placebo use in vaccine trials: recommendations of a WH...

work page doi:10.1056/nejmoa0908492 2014

[5] [6]

Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies

"Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies." Ann Intern Med 163 (2):127‐34. doi: 10.7326/M14‐1741. US Food and Drug Administration. 1998. Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. Technical report. US Food and Drug Administration. 2012. "Food and Dru...

work page doi:10.7326/m14 1998

[6] [7]

pre‐exposure prophylaxis, PrEP) (Grant et al

and HIV‐uninfected persons (e.g. pre‐exposure prophylaxis, PrEP) (Grant et al. 2010, Molina et al. 2015, Baeten et al. 2012, McCormack et al. 2016). Behavioral interventions such as individual‐level risk reduction counseling have not demonstrated efficacy in randomized controlled trials in preventing sexual transmission of HIV [summarized in (Padian et al...

work page 2010

[7] [8]

Compile, Analyze and Tally NAb Panels

for further discussion of this point]. For instance, medical male circumcision is durably efficacious after a single invasive procedure, whereas daily pill‐taking (e.g. oral PrEP) is non‐invasive and requires daily or near‐daily adherence (Donnell et al. 2014, Murnane et al. 2015). HIV prevention remains an area of intense research, and additional types o...

work page doi:10.1126/science.1193748 2014

[8] [9]

Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention

doi: 10.1056/NEJMoa1506273. Murnane, P. M., E. R. Brown, D. Donnell, R. Y. Coley, N. Mugo, A. Mujugira, C. Celum, J. M. Baeten, and E. P. Study Team Partners Pr. 2015. "Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention." Am J Epidemiol 182 (10):848‐...

work page doi:10.1056/nejmoa1506273 2015